Current concepts in the management of rheumatoid arthritis.
- Author:
Yoshiya TANAKA
1
Author Information
- Publication Type:Research Support, Non-U.S. Gov't ; Review
- Keywords: Arthritis, rheumatoid; Antirheumatic agents; Biological antirheumatic agents; Remission; Janus kinase inhibitor
- MeSH: Administration, Oral; Antirheumatic Agents/*administration & dosage/adverse effects; Arthritis, Rheumatoid/diagnosis/*drug therapy/metabolism/physiopathology; Biological Products/administration & dosage; Disability Evaluation; Drug Administration Schedule; Humans; Janus Kinases/antagonists & inhibitors/metabolism; Molecular Targeted Therapy; Predictive Value of Tests; Protein Kinase Inhibitors/administration & dosage; Recovery of Function; Remission Induction; Signal Transduction/drug effects; Treatment Outcome; Tumor Necrosis Factor-alpha/antagonists & inhibitors/metabolism
- From:The Korean Journal of Internal Medicine 2016;31(2):210-218
- CountryRepublic of Korea
- Language:English
- Abstract: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction that causes significant morbidity and mortality. However, the combined use of methotrexate, a synthetic disease-modifying antirheumatic drug (DMARD), and biologic DMARD has revolutionized treatment of RA. Clinical remission is now realistic targets, achieved by a large proportion of RA patients, and rapid and appropriate induction of remission by intensive treatment with biological DMARD and methotrexate is prerequisite to halt joint damage and functional disabilities. However, biological DMARD is limited to intravenous or subcutaneous uses and orally available small but strong molecules have been developed. Oral administration of tofacitinib targeting the Janus kinase (JAK) is significantly effective than placebo in active patients with methotrexatenaive, inadequately responsive to methotrexate or tumor necrosis factor (TNF)-inhibitors. The efficacy was rapid and as strong as adalimumab, a TNF-inhibitor. Meanwhile, association of tofacitinib on carcinogenicity and malignancy is under debate and further investigation on post-marketing survey would be warranted. On the other hand, discontinuation of a biological DMARD without disease flare is our next goal and desirable from the standpoint of risk reduction and cost effectiveness, especially for patients with clinical remission. Recent reports indicate that more than half of early RA patients could discontinue TNF-targeted biological DMARD without clinical flare and functional impairment after obtaining clinical remission. Contrarily, for established RA, fewer patients sustained remission after the discontinuation of biological DMARD and "deep remission" at the discontinuation was a key factor to keep the treatment holiday of biological DMARD.
